Success Metrics

Clinical Success Rate
91.0%

Based on 192 completed trials

Completion Rate
91%(192/211)
Active Trials
14(5%)
Results Posted
49%(95 trials)
Terminated
19(7%)

Phase Distribution

Ph phase_1
19
7%
Ph phase_4
40
15%
Ph not_applicable
34
13%
Ph early_phase_1
8
3%
Ph phase_2
68
25%
Ph phase_3
72
26%

Phase Distribution

27

Early Stage

68

Mid Stage

112

Late Stage

Phase Distribution241 total trials
Early Phase 1First-in-human
8(3.3%)
Phase 1Safety & dosage
19(7.9%)
Phase 2Efficacy & side effects
68(28.2%)
Phase 3Large-scale testing
72(29.9%)
Phase 4Post-market surveillance
40(16.6%)
N/ANon-phased studies
34(14.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.1%

192 of 218 finished

Non-Completion Rate

11.9%

26 ended early

Currently Active

14

trials recruiting

Total Trials

272

all time

Status Distribution
Active(20)
Completed(192)
Terminated(26)
Other(34)

Detailed Status

Completed192
unknown34
Terminated19
Recruiting8
Withdrawn7
Active, not recruiting6

Development Timeline

Analytics

Development Status

Total Trials
272
Active
14
Success Rate
91.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 18 (3.3%)
Phase 119 (7.9%)
Phase 268 (28.2%)
Phase 372 (29.9%)
Phase 440 (16.6%)
N/A34 (14.1%)

Trials by Status

not_yet_recruiting41%
withdrawn73%
completed19271%
active_not_recruiting62%
enrolling_by_invitation21%
terminated197%
unknown3413%
recruiting83%

Recent Activity

Clinical Trials (272)

Showing 20 of 272 trialsScroll for more
NCT06296082Phase 2

Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity

Recruiting
NCT06047457Phase 3

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Active Not Recruiting
NCT07561580Not Applicable

Botulinum Toxin Type A for Frontal Hyperhidrosis

Recruiting
NCT06047444Phase 3

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Active Not Recruiting
NCT07399860Phase 2

Botulinum Toxin A Before Hemorrhoidectomy to Prevent Postoperative Pain

Recruiting
NCT06237465Phase 4

Botulinum Toxin-A for Hidradenitis Suppurativa

Withdrawn
NCT06356025Phase 4

Botulinum Toxin Injection in the UES for R-CPD

Active Not Recruiting
NCT07236632Not Applicable

Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized Study

Not Yet Recruiting
NCT05330078Early Phase 1

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

Completed
NCT06349733Early Phase 1

A Dosage-dependent Manner of Botulinum Toxin Type A on the Prevention of Postoperative Scars of Various Anatomic Regions of the Body

Completed
NCT04069897Phase 3

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

Active Not Recruiting
NCT03654066Phase 4

Botox or Botox With Esophageal Dilation in Patients With Achalasia

Enrolling By Invitation
NCT06974617Not Applicable

Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

Recruiting
NCT04965311Phase 2

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

Terminated
NCT04073303Phase 3

BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence

Completed
NCT03381261Phase 4

(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist

Completed
NCT05892770Phase 1

Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia

Active Not Recruiting
NCT02577185Phase 1

An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A

Completed
NCT02969356Phase 4

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

Completed
NCT04970407Phase 1

A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
272